# Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.

> **NCT03257995** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 54 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Indacaterol maleate
- **DRUG:** Indacaterol acetate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03257995
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-05
- **Primary completion:** 2018-01-17
- **Final completion:** 2018-01-18
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03257995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03257995, "Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03257995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*